These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 27527649)
1. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR; Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649 [TBL] [Abstract][Full Text] [Related]
2. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866 [TBL] [Abstract][Full Text] [Related]
3. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO; Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207 [TBL] [Abstract][Full Text] [Related]
4. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Tamura R Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574 [TBL] [Abstract][Full Text] [Related]
5. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099 [TBL] [Abstract][Full Text] [Related]
6. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey. Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219 [TBL] [Abstract][Full Text] [Related]
7. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668 [TBL] [Abstract][Full Text] [Related]
8. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. Sundby RT; Rhodes SD; Komlodi-Pasztor E; Sarnoff H; Grasso V; Upadhyaya M; Kim A; Evans DG; Blakeley JO; Hanemann CO; Bettegowda C Clin Trials; 2024 Feb; 21(1):40-50. PubMed ID: 37904489 [TBL] [Abstract][Full Text] [Related]
9. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741 [TBL] [Abstract][Full Text] [Related]
10. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors. Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153 [TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution. Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Blakeley JO; Plotkin SR Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632 [TBL] [Abstract][Full Text] [Related]
16. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837 [TBL] [Abstract][Full Text] [Related]
17. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315 [TBL] [Abstract][Full Text] [Related]
18. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162 [TBL] [Abstract][Full Text] [Related]
19. Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. Wallis D; Stemmer-Rachamimov A; Adsit S; Korf B; Pichard D; Blakeley J; Sarin KY; Neurology; 2021 Aug; 97(7 Suppl 1):S42-S49. PubMed ID: 34230199 [TBL] [Abstract][Full Text] [Related]